Application of genomics, proteomics and metabolomics in drug discovery, development and clinic

Research output: Contribution to journalReview article

Abstract

Genomics, proteomics and metabolomics are three areas that are routinely applied throughout the drug-development process as well as after a product enters the market. This review discusses all three 'omics, reporting on the key applications, techniques, recent advances and expectations of each. Genomics, mainly through the use of novel and next-generation sequencing techniques, has advanced areas of drug discovery and development through the comparative assessment of normal and diseased-state tissues, transcription and/or expression profiling, side-effect profiling, pharmacogenomics and the identification of biomarkers. Proteomics, through techniques including isotope coded affinity tags, stable isotopic labeling by amino acids in cell culture, isobaric tags for relative and absolute quantification, multidirectional protein identification technology, activity-based probes, protein/peptide arrays, phage displays and two-hybrid systems is utilized in multiple areas through the drug development pipeline including target and lead identification, compound optimization, throughout the clinical trials process and after market analysis. Metabolomics, although the most recent and least developed of the three 'omics considered in this review, provides a significant contribution to drug development through systems biology approaches. Already implemented to some degree in the drug-discovery industry and used in applications spanning target identification through to toxicological analysis, metabolic network understanding is essential in generating future discoveries.
LanguageEnglish
Pages395-413
Number of pages19
JournalTherapeutic Delivery
Volume4
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Metabolomics
Drug Discovery
Genomics
Proteomics
Pharmaceutical Preparations
Protein Array Analysis
Systems Biology
Pharmacogenetics
Drug Industry
Metabolic Networks and Pathways
Isotopes
Bacteriophages
Toxicology
Cell Culture Techniques
Biomarkers
Clinical Trials
Technology
Amino Acids
Peptides
Proteins

Cite this

@article{c9cbad3daa0a4862ab40bfd9decb13c6,
title = "Application of genomics, proteomics and metabolomics in drug discovery, development and clinic",
abstract = "Genomics, proteomics and metabolomics are three areas that are routinely applied throughout the drug-development process as well as after a product enters the market. This review discusses all three 'omics, reporting on the key applications, techniques, recent advances and expectations of each. Genomics, mainly through the use of novel and next-generation sequencing techniques, has advanced areas of drug discovery and development through the comparative assessment of normal and diseased-state tissues, transcription and/or expression profiling, side-effect profiling, pharmacogenomics and the identification of biomarkers. Proteomics, through techniques including isotope coded affinity tags, stable isotopic labeling by amino acids in cell culture, isobaric tags for relative and absolute quantification, multidirectional protein identification technology, activity-based probes, protein/peptide arrays, phage displays and two-hybrid systems is utilized in multiple areas through the drug development pipeline including target and lead identification, compound optimization, throughout the clinical trials process and after market analysis. Metabolomics, although the most recent and least developed of the three 'omics considered in this review, provides a significant contribution to drug development through systems biology approaches. Already implemented to some degree in the drug-discovery industry and used in applications spanning target identification through to toxicological analysis, metabolic network understanding is essential in generating future discoveries.",
author = "Craig Russell and Ayesha Rahman and Mohammed, {Afzal R.}",
year = "2013",
month = "3",
doi = "10.4155/tde.13.4",
language = "English",
volume = "4",
pages = "395--413",
journal = "Therapeutic Delivery",
issn = "2041-5990",
publisher = "Future Science",
number = "3",

}

Application of genomics, proteomics and metabolomics in drug discovery, development and clinic. / Russell, Craig; Rahman, Ayesha; Mohammed, Afzal R.

In: Therapeutic Delivery, Vol. 4, No. 3, 03.2013, p. 395-413.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Application of genomics, proteomics and metabolomics in drug discovery, development and clinic

AU - Russell, Craig

AU - Rahman, Ayesha

AU - Mohammed, Afzal R.

PY - 2013/3

Y1 - 2013/3

N2 - Genomics, proteomics and metabolomics are three areas that are routinely applied throughout the drug-development process as well as after a product enters the market. This review discusses all three 'omics, reporting on the key applications, techniques, recent advances and expectations of each. Genomics, mainly through the use of novel and next-generation sequencing techniques, has advanced areas of drug discovery and development through the comparative assessment of normal and diseased-state tissues, transcription and/or expression profiling, side-effect profiling, pharmacogenomics and the identification of biomarkers. Proteomics, through techniques including isotope coded affinity tags, stable isotopic labeling by amino acids in cell culture, isobaric tags for relative and absolute quantification, multidirectional protein identification technology, activity-based probes, protein/peptide arrays, phage displays and two-hybrid systems is utilized in multiple areas through the drug development pipeline including target and lead identification, compound optimization, throughout the clinical trials process and after market analysis. Metabolomics, although the most recent and least developed of the three 'omics considered in this review, provides a significant contribution to drug development through systems biology approaches. Already implemented to some degree in the drug-discovery industry and used in applications spanning target identification through to toxicological analysis, metabolic network understanding is essential in generating future discoveries.

AB - Genomics, proteomics and metabolomics are three areas that are routinely applied throughout the drug-development process as well as after a product enters the market. This review discusses all three 'omics, reporting on the key applications, techniques, recent advances and expectations of each. Genomics, mainly through the use of novel and next-generation sequencing techniques, has advanced areas of drug discovery and development through the comparative assessment of normal and diseased-state tissues, transcription and/or expression profiling, side-effect profiling, pharmacogenomics and the identification of biomarkers. Proteomics, through techniques including isotope coded affinity tags, stable isotopic labeling by amino acids in cell culture, isobaric tags for relative and absolute quantification, multidirectional protein identification technology, activity-based probes, protein/peptide arrays, phage displays and two-hybrid systems is utilized in multiple areas through the drug development pipeline including target and lead identification, compound optimization, throughout the clinical trials process and after market analysis. Metabolomics, although the most recent and least developed of the three 'omics considered in this review, provides a significant contribution to drug development through systems biology approaches. Already implemented to some degree in the drug-discovery industry and used in applications spanning target identification through to toxicological analysis, metabolic network understanding is essential in generating future discoveries.

UR - http://www.scopus.com/inward/record.url?scp=84874588078&partnerID=8YFLogxK

UR - http://www.future-science.com/doi/abs/10.4155/tde.13.4

U2 - 10.4155/tde.13.4

DO - 10.4155/tde.13.4

M3 - Review article

VL - 4

SP - 395

EP - 413

JO - Therapeutic Delivery

T2 - Therapeutic Delivery

JF - Therapeutic Delivery

SN - 2041-5990

IS - 3

ER -